# OnCo record temsirolimus (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/temsirolimus/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "temsirolimus" ;
  schema:name "Temsirolimus"@en ;
  schema:description "A weekly infusion that was the first drug to extend survival in poor-risk kidney cancer (2007), and in 2024 the first targeted drug to improve outcomes in childhood rhabdomyosarcoma."@en ;
  schema:url <https://onco.cc/drugs/temsirolimus/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Temsirolimus> ;
  owl:sameAs <http://www.wikidata.org/entity/Q7699074> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=temsirolimus> ;
  onco:status "approved" ;
  onco:tag "gap-fill" ;
  onco:modality "Intravenous mTOR inhibitor (rapamycin analogue)" ;
  schema:alternateName "Torisel" ;
  onco:approval "US 2007: Advanced renal cell carcinoma", "EU 2007: Advanced RCC (poor risk); relapsed/refractory mantle cell lymphoma added 2009" ;
  onco:cancers <https://onco.cc/cancers/rcc/>, <https://onco.cc/cancers/rhabdomyosarcoma/>, <https://onco.cc/cancers/mantle-cell-lymphoma/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/>, <https://onco.cc/technologies/pi3k-akt-mtor-inhibitors/> ;
  onco:companies <https://onco.cc/companies/pfizer/> ;
  onco:pathways <https://onco.cc/pathways/pi3k-akt-mtor/>, <https://onco.cc/pathways/hif-vhl/> .